Ivabradine and endothelium: an update

Lucia Dallapellegrina, Edoardo Sciatti and Enrico Vizzardi

Abstract

Ivabradine is a pure heart-rate lowering drug that is nowadays used, accordingly to the last ESC Guidelines, to reduce mortality and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction and in symptomatic patients with inappropriate sinus tachycardia. Moreover, interesting effect of ivabradine on endothelial and myocardial function and on oxidative stress and inflammation pathways are progressively emerging. The aim of this paper is to highlight newer evidences about ivabradine effect (and consequently possible future application of the drug) in pathological settings different from guidelines-based clinical practice.

Keywords: CAD, diastolic function, endothelium, HFpEF, Ivabradine, oxidative stress, ventricular-arterial coupling

Pharmacology of ivabradine and current indications

Ivabradine is a pure heart rate (HR)-lowering drug. It acts specifically blocking the If (“funny”) current in the sinoatrial node,1 where myocytes generate a spontaneous slow diastolic depolarization and a subsequent action potential. Ivabradine is highly selective for If channels (A), blocking them by entering their pore from the intracellular side in a concentration-dependent manner only when the channel is open.2,3 It reduces the firing rate of the pacemaker cells in the sinoatrial node without affecting the duration of the action potential and without interfering with other ionic currents.2,4 Acting only on pacemaker cells, ivabradine is not effective during atrial fibrillation. Moreover, If inhibition is dependent on the frequency of channel opening, the voltage, and the sodium concentration; because of this, the effect in enhanced at higher HR.3

In chronic heart failure (HF), the increase in HR following sympathetic activation is related to greater morbidity and mortality,3 although tachycardia is one of the first compensatory mechanisms of left ventricular (LV) contractile dysfunction. A novel aspect of ivabradine is its selectivity and specificity for pacemaker If channels6: ivabradine does not affect myocardial contractility, preserves cardiac output, and significantly enhances stroke volume and systolic stroke work, without affecting blood pressure, unlike beta-blockers and non-dihydropyridine calcium channel blockers.7 Many clinical trials have demonstrated both a significant reduction in nonfatal myocardial infarction and a decrease in hospitalization rate for HF in patients LV systolic dysfunction and sinus rhythm with HR ≥70 bpm treated with ivabradine.8,9 In those patients, the drug was shown to improve LV reverse remodelling,10 quality of life,11 and exercise capacity.12 Several sub-studies obtained from the SHIFT trial highlighted the positive effects of ivabradine on LV volumes and ejection fraction (LVEF) on ventricular-arterial coupling (VAC), and, especially, on aortic elastance (Ea).9,10,13 On the other hand, in patients who had stable coronary artery disease (CAD) without clinical HF, the use of ivabradine did not show an improvement in the risk of cardiovascular events in the SIGNIFY trial,14 suggesting reduced beneficial effect in the absence of LV dysfunction and the related neurohormonal activation.

According to the results of the SHIFT and BEAUTIFUL trials,8,9 in the latest European Society of Cardiology (ESC) guidelines for the management of HF ivabradine is recommended in

http://tac.sagepub.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
class IIa to reduce CV mortality and HF hospitalization in symptomatic patients with LVEF \(\leq 35\%\) and resting HR \(\geq 70\) bpm in sinus rhythm despite the maximum tolerated dose of beta-blocker, angiotensin-converting-enzyme (ACE) inhibitor (or angiotensin receptor blocker) and mineralocorticoid receptor antagonist (or angiotensin receptor blocker) (level of evidence B), or in those not tolerating or having contraindications to beta-blocker, already receiving ACE inhibitor (or angiotensin receptor blocker) and mineralocorticoid receptor antagonist (or angiotensin receptor blocker) (level of evidence C).\(^{15}\)

Ivabradine is also recommended alone or in association with a beta-blocker in symptomatic patients with inappropriate sinus tachycardia (class IIa, level of evidence B).\(^{16}\) Recent evidence shows that this drug can be an effective alternative to amiodarone in children with post-operative junctional ectopic tachycardia, the commonest tachyarrhythmia in the early post-operative period in children undergoing open-heart surgery.\(^{17–19}\)

**Effect of ivabradine on endothelial function**

In a recent study, our workgroup demonstrated the efficacy of ivabradine (5 mg two times a day on top of optimized medical therapy for HF) in the improvement of echocardiographic stroke volume, VAC, and endothelial function evaluated with EndoPAT device in patients affected by chronic HF with LV dysfunction.\(^{20}\)

Many previous studies have shown the interaction between HR, \(E_a\), and arterial stiffness, both in animal models and in humans.\(^{21–29}\) These data are consistent with ours, suggesting that blood vessels can adapt to increased mechanic wall stress changing their structure, benefitting from ivabradine-induced HR reduction, with a final improvement of \(E_a\) and VAC. According to previous evidence, the effect might be predominantly on the arterial system and less on LV end-systolic elastance \((Ees)\).\(^{30}\) Similar findings about endothelial function and \(E_a\) were recently confirmed in patients with CAD, in which ivabradine improved arterial stiffness, endothelial function, aortic distensibility, and aortic cyclic strain on magnetic resonance imaging (MRI) over a period of 6 months.\(^{31}\) An increased HR is a marker of CAD progression, correlates with cardiovascular mortality,\(^{32–35}\) and is associated with coronary plaque rupture and subclinical inflammation.\(^{36–38}\)

Ivabradine has been shown to reduce oxidative stress in the myocardial wall, circulating angiotensinII levels and expression of angiotensinII receptor.\(^{39–41}\) Moreover, it decreases plasma values of IL-6, tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), MCP-1, norepinephrine, and prevents endothelial nitric oxide synthase (eNOS) uncoupling.\(^{39–46}\) In ApoE-deficient mice, ivabradine showed a protective effect against atherosclerosis development, enhancing anti-apoptotic, anti-inflammatory, and pro-endothelium repair genes, with a concomitant decrease of expression of genes that increase endothelium permeability and favor inflammation and apoptosis.\(^{47}\)

**Effect of ivabradine on myocardial function**

Mechanisms leading to vascular and endothelial dysfunction (i.e., oxidative stress and pro-inflammatory status) mostly overlap pathogenetic pathways that can drive to diastolic dysfunction and HF with preserved LVEF (HFP EF).\(^{48}\) The effect of ivabradine was recently demonstrated positive in relation to LV diastolic function: drug-induced HR lowering led to an improvement in mitral inflow E/A ratio and deceleration time (DT) and pulmonary vein flow S/D ratio in HFP EF patients.\(^{49}\) The gain in diastolic filling related to an improvement in stroke volume and LVEF. An upgrade in diastolic function was also noted in ischaemic patients undergoing exercise stress echocardiography before and after ivabradine introduction; the same was shown for chronotropic reserve and ischaemic threshold (greater duration of exercise and reduced anginal symptoms).\(^{50}\) Tachycardia induced by sympathetic activation in acute HF can lead to a further reduction in stroke volume. Adding ivabradine to inotropic drug treatment in ischaemic acute HF or cardiogenic shock was shown to optimize the lusitropic effect of dobutamine and was associated with an improved diastolic function (enhanced LV early relaxation and prolonged diastolic time), leading to an increased stroke volume compared with omecamtiv mecarbil.\(^{51}\)

In a murine model, ivabradine was shown to be effective in preventing progression from coxsackievirus-induced myocarditis to dilated cardiomyopathy.\(^{52}\) This preventive and therapeutic effect of the drug is related to inhibition of the p38 MAPK.
downregulation of inflammatory responses (in particular, a reduction of the proinflammatory cytokines TNF-α, IL-1β, and IL-6 was observed), and reduction of collagen expression, with a consequent reduction in the fibrogenesis. Moreover, ivabradine could attenuate the expression of Caspase-3 by downregulation of Bax and upregulation of Bcl-2 to prevent the deterioration of cardiac function resulting from ventricular myocyte loss by cardiomyocyte apoptosis.

Table 1 summarizes the results of the newer cited clinical trials (published after our last work) conducted using ivabradine in pathological settings different from guideline-based clinical practice. It must be highlighted that those studies were conducted in small cohorts of patients, with a short time of drug administration and without long-term follow up and prognostic evaluation. Those results are really encouraging and bring hope for a wider use of ivabradine in different clinical settings, but stronger evidence from large prospective clinical trials is still needed.

### Conclusion

There is strong evidence for the potentially negative effect of increased HR in endothelial and vascular function and in myocardial function. Ivabradine has a pure HR-lowering effect with a clear impact in the hemodynamic setting, but newer evidence has emerged about its putative influence on many cellular mechanisms. For this reason, this drug is increasingly considered as a potential reversing pharmacological molecule, demonstrating correlation with improvement in oxidative and inflammatory status, endothelial function, arterial stiffness, and diastolic function.

### Conflict of interest statement

The authors declare that there is no conflict of interest.

### Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

### ORCID iD

Edoardo Sciatti  [https://orcid.org/0000-0002-5770-3562](https://orcid.org/0000-0002-5770-3562)
References

1. Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. *Br J Pharmacol* 1994; 112: 37–42.

2. Bois P, Bescond J, Renaudon B, et al. Mode of action of Bradykinin ag. 247 on the sinoatrial node in the ovine heart. *Am J Physiol* 1994; 267: H1051–H1057.

3. Bonadei I, Vizzardi E, Sciatti E, et al. Stereoselective in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. *Eur J Pharmacol* 1997; 339: 41–51.

4. Thollon C, Bidouard JP, Cambarrat C, et al. Effects of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). *Int J Cardiol* 2011; 151: 218–224.

5. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. *N Engl J Med* 2014; 371: 1091–1099.

6. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891–975.

7. Brugada J, Katritsis DG, Arbelo E, et al. The importance of reducing heart rate in cardiovascular diseases: effects of ivabradine. *Minerva Med* 2011; 102: 373–379.

8. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. *Eur J Heart Fail* 2008; 10: 550–555.

9. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo-controlled trial. *Lancet* 2008; 372: 807–816.

10. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010; 376: 875–885.

11. Tardif JC, O’Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. *Eur Heart J* 2011; 32: 2507–2515.

12. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). *Int J Cardiol* 2011; 151: 218–224.

13. Reil JC, Tardif JC, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. *J Am Coll Cardiol* 2013; 62: 1977–1985.

14. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. *N Engl J Med* 2014; 371: 1091–1099.

15. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891–975.

16. Brugada J, Katritsis DG, Arbelo E, et al. The importance of reducing heart rate in cardiovascular diseases: effects of ivabradine. *Minerva Med* 2011; 102: 373–379.

17. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. *Eur J Heart Fail* 2008; 10: 550–555.

18. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo-controlled trial. *Lancet* 2008; 372: 807–816.

19. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010; 376: 875–885.

20. Tardif JC, O’Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. *Eur Heart J* 2011; 32: 2507–2515.

21. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). *Int J Cardiol* 2011; 151: 218–224.

22. Freeman GL and Colston JT. Role of ventricular-arterial coupling in cardiac response to increased contractility in closed-chest dogs. *J Clin Invest* 1990; 86: 1278–1284.

23. Mircoli L, Mangoni AA, Giannattasio C, et al. Heart rate-dependent stiffening of large arteries
in intact and sympathectomized rats. *Hypertension* 1999; 34: 598–602.

24. Mangoni AM, Miccoli L, Giannattasio C, et al. Heart rate-dependence of arterial distensibility in vivo. *J Hypertens* 1996; 14: 897–901.

25. Sa Cunha R, Pannier B, Benetos A, et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. *J Hypertens* 1997; 15: 1423–1430.

26. Giannattasio C, Vincenti A, Failla M, et al. Effects of heart rate changes on arterial distensibility in humans. *Hypertension* 2003; 42: 253–256.

27. Maurer MS, Sackner-Bernstein JD, El-Khouy Rumbarger L, et al. Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure. *Circ Heart Fail* 2009; 2: 189–196.

28. Tan I, Kiat H, Barin E, et al. Effects of pacing modality on noninvasive assessment of heart rate dependency of indices of large artery function. *J Appl Physiol* 2016; 121: 771–780.

29. Liang YL, Gatzka CD, Du XJ, et al. Effects of heart rate on arterial compliance in men. *Clin Exp Pharmacol Physiol* 1999; 26: 342–346.

30. Di Francesco D and Camm JA. Heart rate lowering by specific and selective I(I) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. *Drugs* 2004; 64: 1757–1765.

31. Hohneck AL, Fries P, Ströder J, et al. Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease. *J Hypertens* 2019; 37: 1023–1031.

32. Custodis F, Schirmer SH, Baumhäkel M, et al. Vascular pathophysiology in response to increased heart rate. *J Am Coll Cardiol* 2010; 56: 1973–1983.

33. Fox KM and Ferrari R. Heart rate: a forgotten link in coronary artery disease? *Nat Rev Cardiol* 2011; 8: 369–379.

34. Kaplan JR, Manuck SB and Clarkson TB. The influence of heart rate on coronary artery atherosclerosis. *J Cardiovasc Pharmacol* 1987; 10: S100–S103.

35. Perski A, Ohlson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. *Am Heart J* 1992; 123: 609–616.

36. Lerman A and Zeiher AM. Endothelial function: cardiac events. *Circulation* 2005; 111: 363–368.

37. Yeboah J, Crouse JR, Hsu FC, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the cardiovascular health study. *Circulation* 2007; 115: 2390–2397.

38. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow mediated dilation for incident cardiovascular events in a population based study: the multi-ethnic study of atherosclerosis. *Circulation* 2009; 120: 502–509.

39. Leite-Moreira A, Correia-Pinto J and Gillebert TC. Afterload induced changes in myocardial relaxation A mechanism for diastolic dysfunction. *Cardiovasc Res* 1999; 43: 344–353.

40. Lei L, Zhou R, Zheng W, et al. Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart. *Circulation* 2004; 110: 796–802.

41. Custodis F, Baumhäkel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. *Circulation* 2008; 117: 2377–2387.

42. Yue-Chun L, Teng Z and Na-Dan Z. Comparison of effects of ivabradine versus carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. *PLoS One* 2012; 7: e93994.

43. Sabbah HN, Gupta RC, Kohli S, et al. Heart rate reduction with ivabradine improves left ventricular function and reverses multiple pathological maladaptations in dogs with chronic heart failure. *ESC Heart Fail* 2014; 1: 94–102.

44. Kroller-Schon S, Schulz E, Wenzel P, et al. Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress. *Basic Res Cardiol* 2011; 106: 1147–1158.

45. Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. *Br J Pharmacol* 2008; 155: 970–971.

46. Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and β-blockade on left ventricular relaxation during exercise. *Am J Physiol Heart Circ Physiol* 2002; 282: H672–H679.

47. Aquila G, Morelli MB, Vicceli Dalla Sega F, et al. Heart rate reduction with ivabradine in the early phase of atherosclerosis is protective in the
endothelium of ApoE-deficient mice. *J Physiol Pharmacol* 2018; 69: 35–52.

48. Paulus WJ and Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol* 2013; 62: 263–271.

49. Cacciapuoti F, Magro VM, Caturano M, et al. The role of ivabradine in diastolic heart failure with preserved ejection fraction. A doppler-echocardiographic study. *J Cardiovasc Echogr* 2017; 27: 126–131.

50. Calcagno S, Infusino F, Dettori O, et al. Effects of ivabradine on residual myocardial ischemia after PCI evaluated by stress echocardiography. *Cardiol Res Pract* 2019; 2019: 9185876.

51. Ronning L, Bakkehaug JP, Rødland L, et al. Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. *Physiol Rep* 2018, 6: e13879.

52. Gammone MA, Riccioni G, Massari F, et al. Beneficial effect of ivabradine against cardiovascular diseases. *Front Biosci (Schol Ed)* 2020; 12: 161–172.

53. Yue-Chun L, Guang-Yi C, Li-Sha G, et al. The protective effects of ivabradine in preventing progression from viral myocarditis to dilated cardiomyopathy. *Front Pharmacol* 2016; 7: 408.

54. Li-Sha G, Li L, De-Pu Z, et al. Ivabradine treatment reduces cardiomyocyte apoptosis in a murine model of chronic viral myocarditis. *Front Pharmacol* 2018; 9: 182.